Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC

Drug resistance is a major obstacle to curative cancer therapies, and increased understanding of the molecular events contributing to resistance would enable better prediction of therapy response, as well as contribute to new targets for combination therapy. Here we have analyzed the early molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou Tran, Yan, Minozada, Rezan, Cao, Xiaofang, Johansson, Henrik J., Branca, Rui M., Seashore-Ludlow, Brinton, Orre, Lukas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Biochemistry and Molecular Biology 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261823/
https://www.ncbi.nlm.nih.gov/pubmed/32234966
http://dx.doi.org/10.1074/mcp.RA120.002036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261823/
https://www.ncbi.nlm.nih.gov/pubmed/32234966
http://dx.doi.org/10.1074/mcp.RA120.002036

Ejemplares similares